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LETTER TO THE EDITOR
The Proportion of
Patients with
Metastatic Non-small
Cell Lung Cancer
Potentially Eligible for
Treatment with
Bevacizumab: A Single
Institutional Survey
To the Editor:
Lung cancer is the leading cause ofcancer-related mortality in the
United States. Non-small cell lung can-
cer (NSCLC) accounts for more than
85% of newly diagnosed lung cancers.1
Nearly 40% of patients with NSCLC
present with metastatic disease.2 Che-
motherapy for advanced stage NSCLC
provides only modest improvement in
the overall survival.3,4 Addition of bev-
acizumab, an antibody to vascular endo-
thelial growth factor, to paclitaxel and
carboplatin improved survival in a se-
lected group of patients with advanced
NSCLC in the Eastern Cooperative
Group Oncology (ECOG) study.5 How-
ever, patients with a significant history
of hemoptysis, squamous histology, or
brain metastases were excluded from the
ECOG study. Moreover, patients on an-
ticoagulant therapy and those with poor
performance status were also not en-
rolled in this study. It is unclear what
proportion of patients with metastatic
NSCLC is eligible to receive therapy
with bevacizumab.
We conducted a retrospective
analysis of 1553 consecutive patients
with stage IV metastatic NSCLC diag-
nosed at Washington University/Alvin J.
Siteman Cancer Center from October of
1991 and December of 2005 to estimate
the proportion of patients who would be
eligible for therapy with bevacizumab as
defined by the ECOG study referred to
earlier. Because the history of “signifi-
cant” hemoptysis (as defined by the
ECOG study) was not recorded, we fo-
cused our attention on two major issues:
squamous histology and the presence of
brain metastasis at the time of initial
presentation. Of the 1553 patients with
stage IV NSCLC, 378 patients (24.3%)
had squamous cell histology and 467
patients (30.1%) had brain metastasis at
presentation. A total of 738 patients
(47.5%) had a squamous histology
and/or presented with brain metastasis
and hence did not meet the guidelines
for treatment with anti–vascular endo-
thelial growth factor therapy. The actual
proportion of patients with advanced
stage NSCLC who would be eligible for
bevacizumab is likely to be less than
52% because we did not take into con-
sideration the other risk factors (pres-
ence of significant history of hemopty-
sis, concurrent anticoagulation therapy,
and performance status) that might pre-
clude the use of bevacizumab.
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